2024 05 v.54 876-888
胰岛素样生长因子信号轴与其抑制剂在肿瘤中的作用
基金项目(Foundation):
国家自然科学基金面上项目(32170618)
邮箱(Email):
DOI:
10.16152/j.cnki.xdxbzr.2024-05-010
中文作者单位:
西北大学生命科学学院/西部资源生物与现代生物技术教育部重点实验室;
摘要(Abstract):
胰岛素样生长因子(IGFs)是一种体内平衡调节因子，参与全身多种生理、合成和代谢过程，在促进生长中起着关键的自分泌、旁分泌和内分泌作用，涉及多种组织器官内细胞增殖、分化和凋亡的调节。大量体内、体外实验及临床报道发现IGFs分子的异常表达在各种呼吸系统、消化道恶性肿瘤、生殖系统肿瘤及其他肿瘤的增殖侵袭过程中都起到十分重要的作用。从临床角度来看，异常表达的IGF信号轴分子可被认定为癌症的诊断标志物、预后因素和现代抗肿瘤治疗的靶点。因此，针对不同肿瘤组织中IGFs变化所引发的下游分子及信号通路改变，配合靶向分子抑制剂进行针对性用药，可能成为治疗癌症的新方式。总结了IGFs信号轴在正常人体与癌症组织发展中的变化，并对IGFs信号轴的小分子抑制剂进行归纳，希望能为以后的癌症临床治疗与研究提供借鉴，为未来分子靶向治疗辅助癌症用药提供一定的参考。
关键词(KeyWords):
胰岛素样生长因子;肿瘤;抑制剂;靶点治疗
| 181 | 0 | 1 |
| 下载次数 | 被引频次 | 阅读次数 |
参考文献
[1] BAKER L D,BARSNESS S M,BORSON S,et al.Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults:Results of a controlledtrial[J].Archives of Neurology,2012,69(11):1420-1429.
[2] TREJO J L,PIRIZ J,LLORENS-MARTIN M V,et al.Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects[J].Molecular Psychiatry,2007,12(12):1118-1128.
[3] HOLLY J M P,PERKS C M.Insulin-like growth factor physiology:What we have learned from humanstudies[J].Endocrinology and Metabolism Clinics of North America,2012,41(2):249-263.
[4] KAPLAN S A,COHEN P.REVIEW:The somatomedin hypothesis 2007:50 years later[J].The Journal of Clinical Endocrinology & Metabolism,2007,92(12):4529- 4535.
[5] DEIJEN J B,ARWERT L I,DRENT M L.The GH/IGF-I axis and cognitive changes across a 4-year period in healthy adults[J].ISRN Endocrinology,2011,2011(1):249421.
[6] BOWERS L W,ROSSI E L,O’FLANAGAN C H,et al.The role of the insulin/IGF system in cancer:Lessons learned from clinical trials and the energy balance-cancer link[J].Frontiers in Endocrinology,2015,6:77.
[7] SAMANI A A,YAKAR S,LEROITH D,et al.The role of the IGF system in cancer growth and metastasis:Overview and recent insights[J].Endocrine Reviews,2007,28(1):20- 47.
[8] OSHER E,MACAULAY V M.Therapeutic targeting of the IGF axis[J].Cells,2019,8(8):895.
[9] UNGER C,KRAMER N,UNTERLEUTHNER D,et al.Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms[J].Oncogene,2017,36(38):5341-5355.
[10] YU H,ROHAN T.Role of the insulin-like growth factor family in cancer development and progression[J].JNCI:Journal of the National Cancer Institute,2000,92(18):1472-1489.
[11] TOGNON C E,SORENSEN P H B.Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy[J].Expert OpiniononTherapeutic Targets,2012,16(1):33- 48.
[12] KASPRZAK A,ADAMEK A.The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (review)[J].International Journal of Oncology,2012,41(6):1919-1931.
[13] FIRTH S M,BAXTER R C.Cellular actions of the insulin-like growth factor binding proteins[J].Endocrine Reviews,2002,23(6):824-854.
[14] QUAN H Y,TANG H,FANG L,et al.IGF1(CA)19 and IGFBP-3-202A/C gene polymorphism and cancer risk:A meta-analysis[J].Cell Biochemistry and Biophysics,2014,69(1):169-178.
[15] VIGNERI P G,TIRRò E,PENNISI M S,et al.The insulin/IGF system in colorectal cancer development and resistance to therapy[J].Frontiers in Oncology,2015,5:230.
[16] FU S L,TANG H X,LIAO Y D,et al.Association of preoperative serum IGF-I concentration with clinicopathological parameters in patients with non-small cell lung cancer[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2013,33(2):224-227.
[17] KNACKE H,PIETZNER M,DO K T,et al.Metabolic fingerprints of circulating IGF-1 and the IGF-1/IGFBP-3 ratio:A multifluid metabolomics study[J].The Journal of Clinical Endocrinology and Metabolism,2016,101(12):4730- 4742.
[18] CAO H X,WANG G H,MENG L,et al.Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk:A meta-analysis[J].PLoS One,2012,7(11):e49884.
[19] POHLMAN A W,MOUDGALYA H,JORDANO L,et al.The role of IGF-pathway biomarkers in determining risks,screening,and prognosis in lung cancer[J].Oncotarget,2022,13:393- 407.
[20] TAKANAMI I,IMAMUMA T,HASHIZUME T,et al.Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma[J].Journal of Surgical Oncology,1996,61(3):205-208.
[21] KIM J S,KIM E S,LIU D E,et al.Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer[J].Clinical Lung Cancer,2014,15(3):213-221.
[22] KIM J S,KIM E S,LIU D E,et al.Activation of insulin-like growth factor 1 receptor in patients with non-small-cell lung cancer[J].Oncotarget,2015,6(18):16746-16756.
[23] KARMALI R,LARSON M L,SHAMMO J M,et al.Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia[J].Leukemia & Lymphoma,2015,56(11):3135-3142.
[24] XU G J,CHU J S,SHI Y,et al.The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor[J].Growth Hormone & IGF Research,2022,66:101499.
[25] YAN X D,YAO M,WANG L,et al.Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation[J].World Journal of Gastroenterology,2013,19(36):6084-6092.
[26] HUANG X P,ZHOU W H,ZHANG Y F.Genetic variations in the IGF-IGFR-IGFBP axis confer susceptibility to lung and esophageal cancer[J].Genetics and Molecular Research,2014,13(1):2107-2119.
[27] KUNH H,FRILLE A,PETERSE M A,et al.IGFBP3 inhibits tumor growth and invasion of lung cancer cells and is associated with improved survival in lung cancer patients[J].Translational Oncology,2023,27:101566.
[28] LIU P,SUN Y H,LIU S,et al.SY-707,an ALK/FAK/IGF1R inhibitor,suppresses growth and metastasis of breast cancer cells[J].Acta Biochimica et Biophysica Sinica,2022,54(2):252-260.
[29] NUR S,OZTURK A,KAVAS M,et al.IGFBP- 4:A promising biomarker for lung cancer[J].Journal of Medical Biochemistry,2021,40(3):237-244.
[30] YAO R S,WANG Y A,LUBET R A,et al.Differentially expressed genes associated with mouse lung tumor progression[J].Oncogene,2002,21(37):5814-5821.
[31] GUO B L,LV Z,CUI C G,et al.IGF-1R transported to the cell nuclei to regulate the proliferation of breast cancer cells[J].Cell Biochemistry and Biophysics,2021,79(4):801-813.
[32] BAHHNASSY A,MOHANAD M,SHAARAWY S,et al.Transforming growth factor-β,insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A:Prognostic and predictive markers in triple-negative and non-triple-negative breast cancer[J].Molecular Medicine Reports,2015,12(1):851- 864.
[33] HARTOG H,BOEZEN H M,DE JONG M M,et al.Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer[J].The Breast,2013,22(6):1155-1160.
[34] HAMILTON N,MáRQUEZ-GARBáN D,MAH V,et al.Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer[J].BioMed Research International,2015,2015(1):925703.
[35] KHADKA V S,NASU M,DENG Y P,et al.Circulating microRNA biomarker for detecting breast cancer in high-risk benign breast tumors[J].International Journal of Molecular Sciences,2023,24(8):7553.
[36] KALLEDS?E L,DRAGSTED L O,HANSEN L,et al.The insulin-like growth factor family and breast cancer prognosis:A prospective cohort study among postmenopausal women in Denmark[J].Growth Hormone & IGF Research:Official Journal of the Growth Hormone Research Society and the International IGF Research Society,2019,44:33- 42.
[37] RICHARDSONA E,HAMILTON N,DAVIS W,et al.Insulin-like growth factor-2(IGF-2)activates estrogen receptor-α and-β via the IGF-1 and the insulin receptors in breast cancer cells[J].Growth Factors,2011,29(2/3):82-93.
[38] SUN W Y,YUN H Y,SONG Y J,et al.Insulin-like growth factor 1 receptor expression in breast cancer tissue and mammographic density [J].Molecular and Clinical Oncology,2015,3(3):572-580.
[39] SHIN S J,GONG G,LEE H J,et al.Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer[J].Journal of Breast Cancer,2014,17(2):113-120.
[40] OBR A,KUMAR S,BIRGE R,et al.Abstract 3617:A paradigm shift for insulin-like growth factor 1 receptor function in triple negative breast cancers[J].Cancer Research,2017,77(13):3617.
[41] DE GROOT S,CHAREHBILI A,VAN LAARHOVEN H W M,et al.Insulin-like growth factor 1 receptor expression and IGF1R 3129G> T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients:Results from the NEOZOTAC trial (BOOG 2010-01)[J].Breast Cancer Research:BCR,2016,18(1):3.
[42] YAN J,YANG X,LI L,et al.Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma[J].Oncology Letters,2017,13(5):3395-3402.
[43] BACH L A.IGF-binding proteins[J].Journal of Molecular Endocrinology,2018,61(1):T11-T28.
[44] HOEFLICH A,RUSSO V C.Physiology and pathophysiology of IGFBP-1 and IGFBP-2-consensus and dissent on metabolic control and malignant potential[J].Best Practice & Research Clinical Endocrinology & Metabolism,2015,29(5):685-700.
[45] CONWAY J R W,DIN? D D,FOLLAIN G,et al.IGFBP2 secretion by mammary adipocytes limits breast cancer invasion[J].Science Advances,2023,9(28):e1840.
[46] HORNE H N,SHERMAN M E,PFEIFFER R M,et al.Circulating insulin-like growth factor-I,insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast:A cross-sectional study of women with benign breast disease[J].Breast Cancer Research:BCR,2016,18(1):24.
[47] ARAFAT H M,OMAR J,SHAFII N,et al.The association between the serum level of IGF-1 and IGFBP-3 and the risk of breast cancer among women in the gaza strip[J].Asian Pac J Cancer Prev,2023,24(2):717-723.
[48] DITTMER J.Biological effects and regulation of IGFBP5 in breast cancer[J].Frontiers in Endocrinology,2022,13:983793.
[49] WANG W Y,LIM K G,FENG M,et al.KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to PI3K/AKT inhibitor treatment in breast cancer[J].Molecular Cancer Therapeutics,2018,17(9):1973-1983.
[50] ROSENDAHL A H,BJ?RNER S,R?DSTR?M M Y,et al.Pre-and postoperative circulating IGF-I,IGFBP-3,and IGFBP-7 levels in relation to endocrine treatment and breast cancer recurrence:A nested case-control study[J].Frontiers in Oncology,2021,11:626058.
[51] HIMOTO T,TANI J,MIYOSHI H,et al.The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance[J].Nutrition Research,2013,33(1):27-33.
[52] ESPELUND U,GR?NB?K H,VILLADSEN G E,et al.The circulating IGF system in hepatocellular carcinoma:The impact of liver status and treatment[J].Growth Hormone & IGF Research,2015,25(4):174-181.
[53] LIU S,LIU Y H,JIANG X W.Prognostic significance of serum insulin-like growth factor-1 in patients with hepatocellular carcinoma following transarterial chemoembolization[J].Experimental and Therapeutic Medicine,2016,11(2):607-612.
[54] LACIN S,YALCIN S,KARAKAS Y,et al.Prognostic significance of serum insulin-like growth factor-1 in hepatocellular cancer patients:A validation study[J].Journal of Hepatocellular Carcinoma,2020,7:143-153.
[55] VILLANUEVA A,PORTELA A,SAYOLS S,et al.DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma[J].Hepatology,2015,61(6):1945-1956.
[56] WHITTAKER S,MARAIS R,ZHU A X.The role of signaling pathways in the development and treatment of hepatocellular carcinoma[J].Oncogene,2010,29(36):4989-5005.
[57] COUVERT P,CARRIé A,DU MONTCEL S T,et al.Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of patients with hepatitis C related cirrhosis or hepatocellular carcinoma[J].Clinics and Research in Hepatology and Gastroenterology,2012,36(4):345-351.
[58] QIAN J,YAO D F,DONG Z Z,et al.Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma[J].American Journal of Clinical Pathology,2010,134(5):799-806.
[59] TAI B J,YAO M,ZHENG W J,et al.Alteration of oncogenic IGF-II gene methylation status associates with hepatocyte malignant transformation[J].Hepatobiliary&Pancreatic Diseases International:HBPD INT,2019,18(2):158-163.
[60] DAI B,RUAN B,WU J,et al.Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma[J].International Journal of Clinical and Experimental Pathology,2014,7(9):5645-5654.
[61] YAN J J,YANG X Z,LI L,et al.Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma[J].Oncology Letters,2017,13(5):3395-3402.
[62] REGEL I,EICHENMüLLER M,JOPPIEN S,et al.IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors[J].Molecular Cancer,2012,11:9.
[63] OLGA PEMíA,ROSAS R ,JULIA JIMéNEZ,et al.Determination of IGFBP-3 methylation levels at ctDNA could be a prognostic biomarker in advanced stages of NSCLC[J].IBJ Plus,May 2018,DOI:10.24217/2531-0151.18v1s2.00041.
[64] BROWN K M,XUE A Q,SMITH R C,et al.Cancer-associated stroma reveals prognostic biomarkers and novel insights into the tumour microenvironment of colorectal cancer and colorectal liver metastases[J].Cancer Medicine,2022,11(2):492-506.
[65] CHEN D,YOO B K,SANTHEKADUR P K,et al.Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma[J].Clinical Cancer Research,2011,17(21):6693-6701.
[66] BIE C Q,CHEN Y F,TANG H J,et al.Insulin-like growth factor 1 receptor drives hepatocellular carcinoma growth and invasion by activating Stat3-midkine-Stat3 loop[J].Digestive Diseases and Sciences,2022,67(2):569-584.
[67] DACOSTA S A,SCHUMAKER L M,ELLIS M J.Mannose 6-phosphate/insulin-like growth factor 2 receptor,a bona fide tumor suppressor gene or just a promising candidate?[J].Journal of Mammary Gland Biology and Neoplasia,2000,5(1):85-94.
[68] LAUTEM A,SIMON F,HOPPE-LOTICHIUS M,et al.Expression and prognostic significance of insulin-like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization[J].Oncology Reports,2019,41(4):2299-2310.
[69] KNUPPEL A,FENSOM G K,WATTS E L,et al.Circulating insulin-like growth factor-I concentrations and risk of 30 cancers:Prospective analyses in UK biobank[J].Cancer Research,2020,80(18):4014-4021.
[70] PETERS G,GONGOLL S,LANGNER C,et al.IGF-1R,IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer[J].Virchows Archiv:An International Journal of Pathology,2003,443(2):139-145.
[71] 王志明，蒲九君，孙彦龙，等.IGF-1和IGF-1R在无功能性垂体腺瘤中的表达及意义[J].第三军医大学学报，2015,37(13):1367-1372.WANG Z M,PU J J,SUN Y L,et al.Expression of insulin-like growth factor 1 and its receptor inhuman non-functioning pituitary adenomas:Correlation with invasiveness and recurrence[J].Journal of Army Medical University,2015,37(13):1367-1372.
[72] WU X Y,WU Z F,CAO Q H,et al.Insulin-like growth factor receptor-1 overexpression is associated with poor response of rectal cancers to radiotherapy[J].World Journal of Gastroenterology,2014,20(43):16268-16274.
[73] KUMAR A A-O,SINGH P A-O,PANDEY A A-O,et al.IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma[J].Molecular Biology Reports,2020,47(9):6919-6927.
[74] KING E R,ZU Z F,TSANG Y T M,et al.The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma[J].Gynecologic Oncology,2011,123(1):13-18.
[75] LEE S W,LEE S Y,LEE S R,et al.Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia[J].Journal of Gynecologic Oncology,2010,21(3):174-180.
[76] 张瑞敏，芦晓，晏妮.宫颈癌患者血清胰岛素样生长因子1、基质金属蛋白酶9的水平及临床意义[J].癌症进展，2019,17(18):2204-2206,2226.ZHANG R M,LU X,YAN N.Serum levels of insulin-like growth factor 1 and matrix metalloproteinase 9 in patients with cervical cancer and their clinical significance[J].Oncology Progress,2019,17(18):2204-2206,2226.
[77] LI Y S,LIU Q,HE H B,et al.The possible role of insulin-like growth factor-1 in osteosarcoma[J].Current Problems in Cancer,2019,43(3):228-235.
[78] LIU S,LIU Y,JIANG X.Prognostic significance of serum insulin like growth factor 1 in patients with hepatcellular carcinoma following transarterial chemoembolization[J].Experimental and Therapeutic Medicine,2016,11(2):607-612.
[79] 张丽娜，闫华，关宏，等.IGF-2、IGF-1R、IGF-2R在子宫内膜腺癌的表达及临床意义[J].中国妇幼保健，2010,25(29):4284- 4287.ZHANG L N,YAN H,GUAN H,et al.Expressions of IGF-2,IGF-1R and IGF-2R in endometrial adenocarcinoma and clinical significance[J].Maternal and Child Health Care of China,2010,25(29):4284- 4287.
[80] WATTS E L,PEREZ-CORNAGO A,FENSOM G K,et al.Circulating insulin-like growth factors and risks of overall,aggressive and early-onset prostate cancer:A collaborative analysis of 20 prospective studies and Mendelian randomization analysis[J].International Journal of Epidemiology,2023,52(1):71-86.
[81] SHARMA M,SATYAM A,ABHISHEK A,et al.Molecular and circulatory expression of insulin growth factors in Indian females with advanced cervical cancer[J].Asian Pac J Cancer P,2012,13(12):6475- 6479.
[82] LODHIA K A,TIENCHAIANANDA P,HALUSKA P.Understanding the key to targeting the IGF axis in cancer:A biomarker assessment[J].Frontiers in Oncology,2015,5:142.
[83] LIU Y J,QIANG W,SHI J,et al.Expression and significance of IGF-1 and IGF-1R in thyroid nodules[J].Endocrine,2013,44(1):158-164.
[84] FUHRER D,ESZLINGER M,KARGER S,et al.Evaluation of insulin-like growth factor II,cyclooxygenase-2,ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours[J].European Journal of Endocrinology,2005,152(5):785-790.
[85] CAI Q,DOZMOROV M,OH Y.IGFBP-3/IGFBP-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer[J].Cells,2020,9(5):1261.
[86] SCHEDLICH L J,YENSON V M,BAXTER R C.TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells[J].Molecular and Cellular Endocrinology,2013,377(1/2):56-64.
[87] LUTHER G A,LAMPLOT J,CHEN X,et al.IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma[J].Cancer Letters,2013,336(1):222-230.
[88] DE SOUZA R R,OLIVEIRA I D,DEL GIUDICE PANIAGO M,et al.Investigation of IGF2,Hedgehog and fusion gene expression profiles in pediatric sarcomas[J].Growth Hormone & IGF Research,2014,24(4):130-136.
[89] HUANG H J,ANGELO L S,RODON J,et al.R1507,an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody,and EWS/FLI-1 siRNA in Ewing’s sarcoma:Convergence at the IGF/IGFR/Akt axis[J].PLoS One,2011,6(10):e26060.
[90] GENUA M,XU S Q,BURASCHI S,et al.Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells[J].PLoS One,2012,7(6):e40148.
[91] TSAI C W,CHANG W S,XU Y F,et al.Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk[J].Molecular Carcinogenesis,2021,60(11):726-733.
[92] VERHAGEN H J,DE LEEUW D C,ROEMER M G,et al.IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival[J].Cell Death & Disease,2019,5(6):e1300.
[93] CHEN X L,ZHENG J K,ZOU Y Z,et al.IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells[J].Journal of Hematology & Oncology,2013,6(1):72.
[94] KüHNL A,KAISER M,NEUMANN M,et al.High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia[J].Leukemia Research,2011,35(12):1585-1590.
[95] IOANNOU N,SEDDON A M,DALGLEISH A,et al.Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor,NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells[J].BMC Cancer,2013,13:41.
[96] ZHOU H,RAO J,LIN J,et al.The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy[J].Oncology Reports,2011,25(6):1565-1571.
[97] SCHULTZE A,DECKER S,OTTEN J,et al.TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis[J].Investigational New Drugs,2009,28(6):825-833.
[98] NISHIO M,MURAKAMI H,HORIIKE A,et al.Phase I study of ceritinib (LDK378) in Japanese patients with advanced,anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors[J].Journal of Thoracic Oncology,2015,10(7):1058-1066.
[99] YOUSSF C,CUBILLOS-ROJAS M,COMALADA M,et al.Myeloid p38α signaling promotes intestinal IGF-1 production and inflammation-associated tumorigenesis[J].EMBO Molecular Medicine,2018,10(7):e8403.
[100] LIU P,SUN Y H,LIU S,et al.SY-707,an ALK/FAK/IGF1R inhibitor,suppresses growth and metastasis of breast cancer cells[J].Acta BiochimicaetBiophysica Sinica,2022,54(2):252-260.
[101] FEI H D,YUAN Q,MAO L,et al.Assessment of GSK1904529A as a promising anti-osteosarcoma agent[J].Oncotarget,2017,8(30):49646- 49654.
[102] ZHOU F Y,CHEN X G,FAN S,et al.GSK1838705A,an insulin-like growth factor-1 receptor/insulin receptor inhibitor,induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo[J].Onco Targets and Therapy,2015,8:753-760.
[103] WEI Y H,TANG H X,LIAO Y D,et al.Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2015,35(6):834- 841.
[104] PUZANOV I,LINDSAY C R,GOFF L,et al.A phase I study of continuous oral dosing of OSI-906,a dual inhibitor of insulin-like growth factor-1 and insulin receptors,in patients with advanced solid tumors[J].Clinical Cancer Research:an Official Journal of the American Association for Cancer Research,2015,21(4):701-711.
[105] FRANKS S E,JONES R A,BRIAH R,et al.BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549[J].BMC Research Notes,2016,9(1):134.
[106] ZHANG C,ZHAO X N,WANG Z F,et al.Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth,and inducing autophagy as well as cell cycle arrest at the G1 phase[J].Investigational New Drugs,2023,41(3):438-452.
[107] JIN Y,GONG S,SHANG G C,et al.Profiling of a novel circadian clock-related prognostic signature and its role in immune function and response to molecular targeted therapy in pancreatic cancer[J].Aging,2023,15(1):119-133.
[108] KONG Y L,SHEN Y,NI J,et al.Insulin deficiency induces rat renal mesangial cell dysfunction via activation of IGF-1/IGF-1R pathway[J].Acta Pharmacologica Sinica,2016,37(2):217-227.
[109] MAHE M,DUFOUR F,NEYRET-KAHN H,et al.An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers[J].EMBO Molecular Medicine,2018,10(4):e8163.
[110] SUN X,LIANG J,YAO X,et al.The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia[J].Oncotarget,2015,6(34):35478-35495.
[111] MANCARELLA C,MORRIONE A,SCOTLANDI K.Novel regulators of the IGF system in cancer[J].Biomolecules,2021,11(2):273.
[2] TREJO J L,PIRIZ J,LLORENS-MARTIN M V,et al.Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects[J].Molecular Psychiatry,2007,12(12):1118-1128.
[3] HOLLY J M P,PERKS C M.Insulin-like growth factor physiology:What we have learned from humanstudies[J].Endocrinology and Metabolism Clinics of North America,2012,41(2):249-263.
[4] KAPLAN S A,COHEN P.REVIEW:The somatomedin hypothesis 2007:50 years later[J].The Journal of Clinical Endocrinology & Metabolism,2007,92(12):4529- 4535.
[5] DEIJEN J B,ARWERT L I,DRENT M L.The GH/IGF-I axis and cognitive changes across a 4-year period in healthy adults[J].ISRN Endocrinology,2011,2011(1):249421.
[6] BOWERS L W,ROSSI E L,O’FLANAGAN C H,et al.The role of the insulin/IGF system in cancer:Lessons learned from clinical trials and the energy balance-cancer link[J].Frontiers in Endocrinology,2015,6:77.
[7] SAMANI A A,YAKAR S,LEROITH D,et al.The role of the IGF system in cancer growth and metastasis:Overview and recent insights[J].Endocrine Reviews,2007,28(1):20- 47.
[8] OSHER E,MACAULAY V M.Therapeutic targeting of the IGF axis[J].Cells,2019,8(8):895.
[9] UNGER C,KRAMER N,UNTERLEUTHNER D,et al.Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms[J].Oncogene,2017,36(38):5341-5355.
[10] YU H,ROHAN T.Role of the insulin-like growth factor family in cancer development and progression[J].JNCI:Journal of the National Cancer Institute,2000,92(18):1472-1489.
[11] TOGNON C E,SORENSEN P H B.Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy[J].Expert OpiniononTherapeutic Targets,2012,16(1):33- 48.
[12] KASPRZAK A,ADAMEK A.The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (review)[J].International Journal of Oncology,2012,41(6):1919-1931.
[13] FIRTH S M,BAXTER R C.Cellular actions of the insulin-like growth factor binding proteins[J].Endocrine Reviews,2002,23(6):824-854.
[14] QUAN H Y,TANG H,FANG L,et al.IGF1(CA)19 and IGFBP-3-202A/C gene polymorphism and cancer risk:A meta-analysis[J].Cell Biochemistry and Biophysics,2014,69(1):169-178.
[15] VIGNERI P G,TIRRò E,PENNISI M S,et al.The insulin/IGF system in colorectal cancer development and resistance to therapy[J].Frontiers in Oncology,2015,5:230.
[16] FU S L,TANG H X,LIAO Y D,et al.Association of preoperative serum IGF-I concentration with clinicopathological parameters in patients with non-small cell lung cancer[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2013,33(2):224-227.
[17] KNACKE H,PIETZNER M,DO K T,et al.Metabolic fingerprints of circulating IGF-1 and the IGF-1/IGFBP-3 ratio:A multifluid metabolomics study[J].The Journal of Clinical Endocrinology and Metabolism,2016,101(12):4730- 4742.
[18] CAO H X,WANG G H,MENG L,et al.Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk:A meta-analysis[J].PLoS One,2012,7(11):e49884.
[19] POHLMAN A W,MOUDGALYA H,JORDANO L,et al.The role of IGF-pathway biomarkers in determining risks,screening,and prognosis in lung cancer[J].Oncotarget,2022,13:393- 407.
[20] TAKANAMI I,IMAMUMA T,HASHIZUME T,et al.Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma[J].Journal of Surgical Oncology,1996,61(3):205-208.
[21] KIM J S,KIM E S,LIU D E,et al.Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer[J].Clinical Lung Cancer,2014,15(3):213-221.
[22] KIM J S,KIM E S,LIU D E,et al.Activation of insulin-like growth factor 1 receptor in patients with non-small-cell lung cancer[J].Oncotarget,2015,6(18):16746-16756.
[23] KARMALI R,LARSON M L,SHAMMO J M,et al.Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia[J].Leukemia & Lymphoma,2015,56(11):3135-3142.
[24] XU G J,CHU J S,SHI Y,et al.The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor[J].Growth Hormone & IGF Research,2022,66:101499.
[25] YAN X D,YAO M,WANG L,et al.Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation[J].World Journal of Gastroenterology,2013,19(36):6084-6092.
[26] HUANG X P,ZHOU W H,ZHANG Y F.Genetic variations in the IGF-IGFR-IGFBP axis confer susceptibility to lung and esophageal cancer[J].Genetics and Molecular Research,2014,13(1):2107-2119.
[27] KUNH H,FRILLE A,PETERSE M A,et al.IGFBP3 inhibits tumor growth and invasion of lung cancer cells and is associated with improved survival in lung cancer patients[J].Translational Oncology,2023,27:101566.
[28] LIU P,SUN Y H,LIU S,et al.SY-707,an ALK/FAK/IGF1R inhibitor,suppresses growth and metastasis of breast cancer cells[J].Acta Biochimica et Biophysica Sinica,2022,54(2):252-260.
[29] NUR S,OZTURK A,KAVAS M,et al.IGFBP- 4:A promising biomarker for lung cancer[J].Journal of Medical Biochemistry,2021,40(3):237-244.
[30] YAO R S,WANG Y A,LUBET R A,et al.Differentially expressed genes associated with mouse lung tumor progression[J].Oncogene,2002,21(37):5814-5821.
[31] GUO B L,LV Z,CUI C G,et al.IGF-1R transported to the cell nuclei to regulate the proliferation of breast cancer cells[J].Cell Biochemistry and Biophysics,2021,79(4):801-813.
[32] BAHHNASSY A,MOHANAD M,SHAARAWY S,et al.Transforming growth factor-β,insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A:Prognostic and predictive markers in triple-negative and non-triple-negative breast cancer[J].Molecular Medicine Reports,2015,12(1):851- 864.
[33] HARTOG H,BOEZEN H M,DE JONG M M,et al.Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer[J].The Breast,2013,22(6):1155-1160.
[34] HAMILTON N,MáRQUEZ-GARBáN D,MAH V,et al.Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer[J].BioMed Research International,2015,2015(1):925703.
[35] KHADKA V S,NASU M,DENG Y P,et al.Circulating microRNA biomarker for detecting breast cancer in high-risk benign breast tumors[J].International Journal of Molecular Sciences,2023,24(8):7553.
[36] KALLEDS?E L,DRAGSTED L O,HANSEN L,et al.The insulin-like growth factor family and breast cancer prognosis:A prospective cohort study among postmenopausal women in Denmark[J].Growth Hormone & IGF Research:Official Journal of the Growth Hormone Research Society and the International IGF Research Society,2019,44:33- 42.
[37] RICHARDSONA E,HAMILTON N,DAVIS W,et al.Insulin-like growth factor-2(IGF-2)activates estrogen receptor-α and-β via the IGF-1 and the insulin receptors in breast cancer cells[J].Growth Factors,2011,29(2/3):82-93.
[38] SUN W Y,YUN H Y,SONG Y J,et al.Insulin-like growth factor 1 receptor expression in breast cancer tissue and mammographic density [J].Molecular and Clinical Oncology,2015,3(3):572-580.
[39] SHIN S J,GONG G,LEE H J,et al.Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer[J].Journal of Breast Cancer,2014,17(2):113-120.
[40] OBR A,KUMAR S,BIRGE R,et al.Abstract 3617:A paradigm shift for insulin-like growth factor 1 receptor function in triple negative breast cancers[J].Cancer Research,2017,77(13):3617.
[41] DE GROOT S,CHAREHBILI A,VAN LAARHOVEN H W M,et al.Insulin-like growth factor 1 receptor expression and IGF1R 3129G> T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients:Results from the NEOZOTAC trial (BOOG 2010-01)[J].Breast Cancer Research:BCR,2016,18(1):3.
[42] YAN J,YANG X,LI L,et al.Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma[J].Oncology Letters,2017,13(5):3395-3402.
[43] BACH L A.IGF-binding proteins[J].Journal of Molecular Endocrinology,2018,61(1):T11-T28.
[44] HOEFLICH A,RUSSO V C.Physiology and pathophysiology of IGFBP-1 and IGFBP-2-consensus and dissent on metabolic control and malignant potential[J].Best Practice & Research Clinical Endocrinology & Metabolism,2015,29(5):685-700.
[45] CONWAY J R W,DIN? D D,FOLLAIN G,et al.IGFBP2 secretion by mammary adipocytes limits breast cancer invasion[J].Science Advances,2023,9(28):e1840.
[46] HORNE H N,SHERMAN M E,PFEIFFER R M,et al.Circulating insulin-like growth factor-I,insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast:A cross-sectional study of women with benign breast disease[J].Breast Cancer Research:BCR,2016,18(1):24.
[47] ARAFAT H M,OMAR J,SHAFII N,et al.The association between the serum level of IGF-1 and IGFBP-3 and the risk of breast cancer among women in the gaza strip[J].Asian Pac J Cancer Prev,2023,24(2):717-723.
[48] DITTMER J.Biological effects and regulation of IGFBP5 in breast cancer[J].Frontiers in Endocrinology,2022,13:983793.
[49] WANG W Y,LIM K G,FENG M,et al.KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to PI3K/AKT inhibitor treatment in breast cancer[J].Molecular Cancer Therapeutics,2018,17(9):1973-1983.
[50] ROSENDAHL A H,BJ?RNER S,R?DSTR?M M Y,et al.Pre-and postoperative circulating IGF-I,IGFBP-3,and IGFBP-7 levels in relation to endocrine treatment and breast cancer recurrence:A nested case-control study[J].Frontiers in Oncology,2021,11:626058.
[51] HIMOTO T,TANI J,MIYOSHI H,et al.The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance[J].Nutrition Research,2013,33(1):27-33.
[52] ESPELUND U,GR?NB?K H,VILLADSEN G E,et al.The circulating IGF system in hepatocellular carcinoma:The impact of liver status and treatment[J].Growth Hormone & IGF Research,2015,25(4):174-181.
[53] LIU S,LIU Y H,JIANG X W.Prognostic significance of serum insulin-like growth factor-1 in patients with hepatocellular carcinoma following transarterial chemoembolization[J].Experimental and Therapeutic Medicine,2016,11(2):607-612.
[54] LACIN S,YALCIN S,KARAKAS Y,et al.Prognostic significance of serum insulin-like growth factor-1 in hepatocellular cancer patients:A validation study[J].Journal of Hepatocellular Carcinoma,2020,7:143-153.
[55] VILLANUEVA A,PORTELA A,SAYOLS S,et al.DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma[J].Hepatology,2015,61(6):1945-1956.
[56] WHITTAKER S,MARAIS R,ZHU A X.The role of signaling pathways in the development and treatment of hepatocellular carcinoma[J].Oncogene,2010,29(36):4989-5005.
[57] COUVERT P,CARRIé A,DU MONTCEL S T,et al.Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of patients with hepatitis C related cirrhosis or hepatocellular carcinoma[J].Clinics and Research in Hepatology and Gastroenterology,2012,36(4):345-351.
[58] QIAN J,YAO D F,DONG Z Z,et al.Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma[J].American Journal of Clinical Pathology,2010,134(5):799-806.
[59] TAI B J,YAO M,ZHENG W J,et al.Alteration of oncogenic IGF-II gene methylation status associates with hepatocyte malignant transformation[J].Hepatobiliary&Pancreatic Diseases International:HBPD INT,2019,18(2):158-163.
[60] DAI B,RUAN B,WU J,et al.Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma[J].International Journal of Clinical and Experimental Pathology,2014,7(9):5645-5654.
[61] YAN J J,YANG X Z,LI L,et al.Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma[J].Oncology Letters,2017,13(5):3395-3402.
[62] REGEL I,EICHENMüLLER M,JOPPIEN S,et al.IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors[J].Molecular Cancer,2012,11:9.
[63] OLGA PEMíA,ROSAS R ,JULIA JIMéNEZ,et al.Determination of IGFBP-3 methylation levels at ctDNA could be a prognostic biomarker in advanced stages of NSCLC[J].IBJ Plus,May 2018,DOI:10.24217/2531-0151.18v1s2.00041.
[64] BROWN K M,XUE A Q,SMITH R C,et al.Cancer-associated stroma reveals prognostic biomarkers and novel insights into the tumour microenvironment of colorectal cancer and colorectal liver metastases[J].Cancer Medicine,2022,11(2):492-506.
[65] CHEN D,YOO B K,SANTHEKADUR P K,et al.Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma[J].Clinical Cancer Research,2011,17(21):6693-6701.
[66] BIE C Q,CHEN Y F,TANG H J,et al.Insulin-like growth factor 1 receptor drives hepatocellular carcinoma growth and invasion by activating Stat3-midkine-Stat3 loop[J].Digestive Diseases and Sciences,2022,67(2):569-584.
[67] DACOSTA S A,SCHUMAKER L M,ELLIS M J.Mannose 6-phosphate/insulin-like growth factor 2 receptor,a bona fide tumor suppressor gene or just a promising candidate?[J].Journal of Mammary Gland Biology and Neoplasia,2000,5(1):85-94.
[68] LAUTEM A,SIMON F,HOPPE-LOTICHIUS M,et al.Expression and prognostic significance of insulin-like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization[J].Oncology Reports,2019,41(4):2299-2310.
[69] KNUPPEL A,FENSOM G K,WATTS E L,et al.Circulating insulin-like growth factor-I concentrations and risk of 30 cancers:Prospective analyses in UK biobank[J].Cancer Research,2020,80(18):4014-4021.
[70] PETERS G,GONGOLL S,LANGNER C,et al.IGF-1R,IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer[J].Virchows Archiv:An International Journal of Pathology,2003,443(2):139-145.
[71] 王志明，蒲九君，孙彦龙，等.IGF-1和IGF-1R在无功能性垂体腺瘤中的表达及意义[J].第三军医大学学报，2015,37(13):1367-1372.WANG Z M,PU J J,SUN Y L,et al.Expression of insulin-like growth factor 1 and its receptor inhuman non-functioning pituitary adenomas:Correlation with invasiveness and recurrence[J].Journal of Army Medical University,2015,37(13):1367-1372.
[72] WU X Y,WU Z F,CAO Q H,et al.Insulin-like growth factor receptor-1 overexpression is associated with poor response of rectal cancers to radiotherapy[J].World Journal of Gastroenterology,2014,20(43):16268-16274.
[73] KUMAR A A-O,SINGH P A-O,PANDEY A A-O,et al.IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma[J].Molecular Biology Reports,2020,47(9):6919-6927.
[74] KING E R,ZU Z F,TSANG Y T M,et al.The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma[J].Gynecologic Oncology,2011,123(1):13-18.
[75] LEE S W,LEE S Y,LEE S R,et al.Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia[J].Journal of Gynecologic Oncology,2010,21(3):174-180.
[76] 张瑞敏，芦晓，晏妮.宫颈癌患者血清胰岛素样生长因子1、基质金属蛋白酶9的水平及临床意义[J].癌症进展，2019,17(18):2204-2206,2226.ZHANG R M,LU X,YAN N.Serum levels of insulin-like growth factor 1 and matrix metalloproteinase 9 in patients with cervical cancer and their clinical significance[J].Oncology Progress,2019,17(18):2204-2206,2226.
[77] LI Y S,LIU Q,HE H B,et al.The possible role of insulin-like growth factor-1 in osteosarcoma[J].Current Problems in Cancer,2019,43(3):228-235.
[78] LIU S,LIU Y,JIANG X.Prognostic significance of serum insulin like growth factor 1 in patients with hepatcellular carcinoma following transarterial chemoembolization[J].Experimental and Therapeutic Medicine,2016,11(2):607-612.
[79] 张丽娜，闫华，关宏，等.IGF-2、IGF-1R、IGF-2R在子宫内膜腺癌的表达及临床意义[J].中国妇幼保健，2010,25(29):4284- 4287.ZHANG L N,YAN H,GUAN H,et al.Expressions of IGF-2,IGF-1R and IGF-2R in endometrial adenocarcinoma and clinical significance[J].Maternal and Child Health Care of China,2010,25(29):4284- 4287.
[80] WATTS E L,PEREZ-CORNAGO A,FENSOM G K,et al.Circulating insulin-like growth factors and risks of overall,aggressive and early-onset prostate cancer:A collaborative analysis of 20 prospective studies and Mendelian randomization analysis[J].International Journal of Epidemiology,2023,52(1):71-86.
[81] SHARMA M,SATYAM A,ABHISHEK A,et al.Molecular and circulatory expression of insulin growth factors in Indian females with advanced cervical cancer[J].Asian Pac J Cancer P,2012,13(12):6475- 6479.
[82] LODHIA K A,TIENCHAIANANDA P,HALUSKA P.Understanding the key to targeting the IGF axis in cancer:A biomarker assessment[J].Frontiers in Oncology,2015,5:142.
[83] LIU Y J,QIANG W,SHI J,et al.Expression and significance of IGF-1 and IGF-1R in thyroid nodules[J].Endocrine,2013,44(1):158-164.
[84] FUHRER D,ESZLINGER M,KARGER S,et al.Evaluation of insulin-like growth factor II,cyclooxygenase-2,ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours[J].European Journal of Endocrinology,2005,152(5):785-790.
[85] CAI Q,DOZMOROV M,OH Y.IGFBP-3/IGFBP-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer[J].Cells,2020,9(5):1261.
[86] SCHEDLICH L J,YENSON V M,BAXTER R C.TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells[J].Molecular and Cellular Endocrinology,2013,377(1/2):56-64.
[87] LUTHER G A,LAMPLOT J,CHEN X,et al.IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma[J].Cancer Letters,2013,336(1):222-230.
[88] DE SOUZA R R,OLIVEIRA I D,DEL GIUDICE PANIAGO M,et al.Investigation of IGF2,Hedgehog and fusion gene expression profiles in pediatric sarcomas[J].Growth Hormone & IGF Research,2014,24(4):130-136.
[89] HUANG H J,ANGELO L S,RODON J,et al.R1507,an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody,and EWS/FLI-1 siRNA in Ewing’s sarcoma:Convergence at the IGF/IGFR/Akt axis[J].PLoS One,2011,6(10):e26060.
[90] GENUA M,XU S Q,BURASCHI S,et al.Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells[J].PLoS One,2012,7(6):e40148.
[91] TSAI C W,CHANG W S,XU Y F,et al.Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk[J].Molecular Carcinogenesis,2021,60(11):726-733.
[92] VERHAGEN H J,DE LEEUW D C,ROEMER M G,et al.IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival[J].Cell Death & Disease,2019,5(6):e1300.
[93] CHEN X L,ZHENG J K,ZOU Y Z,et al.IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells[J].Journal of Hematology & Oncology,2013,6(1):72.
[94] KüHNL A,KAISER M,NEUMANN M,et al.High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia[J].Leukemia Research,2011,35(12):1585-1590.
[95] IOANNOU N,SEDDON A M,DALGLEISH A,et al.Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor,NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells[J].BMC Cancer,2013,13:41.
[96] ZHOU H,RAO J,LIN J,et al.The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy[J].Oncology Reports,2011,25(6):1565-1571.
[97] SCHULTZE A,DECKER S,OTTEN J,et al.TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis[J].Investigational New Drugs,2009,28(6):825-833.
[98] NISHIO M,MURAKAMI H,HORIIKE A,et al.Phase I study of ceritinib (LDK378) in Japanese patients with advanced,anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors[J].Journal of Thoracic Oncology,2015,10(7):1058-1066.
[99] YOUSSF C,CUBILLOS-ROJAS M,COMALADA M,et al.Myeloid p38α signaling promotes intestinal IGF-1 production and inflammation-associated tumorigenesis[J].EMBO Molecular Medicine,2018,10(7):e8403.
[100] LIU P,SUN Y H,LIU S,et al.SY-707,an ALK/FAK/IGF1R inhibitor,suppresses growth and metastasis of breast cancer cells[J].Acta BiochimicaetBiophysica Sinica,2022,54(2):252-260.
[101] FEI H D,YUAN Q,MAO L,et al.Assessment of GSK1904529A as a promising anti-osteosarcoma agent[J].Oncotarget,2017,8(30):49646- 49654.
[102] ZHOU F Y,CHEN X G,FAN S,et al.GSK1838705A,an insulin-like growth factor-1 receptor/insulin receptor inhibitor,induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo[J].Onco Targets and Therapy,2015,8:753-760.
[103] WEI Y H,TANG H X,LIAO Y D,et al.Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2015,35(6):834- 841.
[104] PUZANOV I,LINDSAY C R,GOFF L,et al.A phase I study of continuous oral dosing of OSI-906,a dual inhibitor of insulin-like growth factor-1 and insulin receptors,in patients with advanced solid tumors[J].Clinical Cancer Research:an Official Journal of the American Association for Cancer Research,2015,21(4):701-711.
[105] FRANKS S E,JONES R A,BRIAH R,et al.BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549[J].BMC Research Notes,2016,9(1):134.
[106] ZHANG C,ZHAO X N,WANG Z F,et al.Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth,and inducing autophagy as well as cell cycle arrest at the G1 phase[J].Investigational New Drugs,2023,41(3):438-452.
[107] JIN Y,GONG S,SHANG G C,et al.Profiling of a novel circadian clock-related prognostic signature and its role in immune function and response to molecular targeted therapy in pancreatic cancer[J].Aging,2023,15(1):119-133.
[108] KONG Y L,SHEN Y,NI J,et al.Insulin deficiency induces rat renal mesangial cell dysfunction via activation of IGF-1/IGF-1R pathway[J].Acta Pharmacologica Sinica,2016,37(2):217-227.
[109] MAHE M,DUFOUR F,NEYRET-KAHN H,et al.An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers[J].EMBO Molecular Medicine,2018,10(4):e8163.
[110] SUN X,LIANG J,YAO X,et al.The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia[J].Oncotarget,2015,6(34):35478-35495.
[111] MANCARELLA C,MORRIONE A,SCOTLANDI K.Novel regulators of the IGF system in cancer[J].Biomolecules,2021,11(2):273.
基本信息:
DOI：10.16152/j.cnki.xdxbzr.2024-05-010
中图分类号:R730.5
引用信息:
[1]田静,付瑶,孙钰等.胰岛素样生长因子信号轴与其抑制剂在肿瘤中的作用[J].西北大学学报(自然科学版),2024,54(05):876-888.DOI:10.16152/j.cnki.xdxbzr.2024-05-010.
基金信息:
国家自然科学基金面上项目(32170618)
暂无数据